Abstract:Background Much effort has been devoted to the discovery of specific mechanisms between drugs and single targets to date. However, as biological systems maintain homeostasis at the level of functional networks robustly controlling the internal environment, such networks commonly contain multiple redundant mechanisms designed to counteract loss or perturbation of a single member of the network. As such, investigation of therapeutics that target dysregulated pathways or processes, rather than single targets, may identify agents that function at a level of the biological organization more relevant to the pathology of complex diseases such as Parkinson’s Disease (PD). Genome-wide association studies (GWAS) in PD have identified common variants underlying disease susceptibility, while gene expression microarray data provide genome-wide transcriptional profiles. These genomic studies can illustrate upstream perturbations causing the dysfunction in signaling pathways and downstream biochemical mechanisms leading to the PD phenotype. We hypothesize that drugs acting at the level of a gene expression module specific to PD can overcome the lack of efficacy associated with targeting a single gene in polygenic diseases. Thus, this approach represents a promising new direction for module-based drug discovery in human diseases such as PD. Results We built a framework that integrates GWAS data with gene co-expression modules from tissues representing three brain regions—the frontal gyrus, the lateral substantia, and the medial substantia in PD patients. Using weighted gene correlation network analysis (WGCNA) software package in R, we conducted enrichment analysis of data from a GWAS of PD. This led to the identification of two over-represented PD-specific gene co-expression network modules: the Br own Module ( Br ) containing 449 genes and the T urquoise module ( T ) containing 905 genes. Further enrichment analysis identified four functional pathways within the Br module (cellular respiration, intracellular transport, energy coupled proton transport against the electrochemical gradient, and microtubule-based movement), and one functional pathway within the T module (M-phase). Next, we utilized drug-protein regulatory relationship databases (DMAP) and developed a D rug E ffect S um S core ( DESS ) to evaluate all candidate drugs that might restore gene expression to normal level across the Br and T modules. Among the drugs with the 12 highest DESS scores, 5 had been reported as potential treatments for PD and 6 hold potential repositioning applications. Conclusion In this study, we present a systems pharmacology framework which draws on genetic data from GWAS and gene expression microarray data to reposition drugs for PD. Our innovative approach integrates gene co-expression modules with biomolecular interaction network analysis to identify network modules critical to the PD pathway and disease mechanism. We quantify the positive effects of drugs in a DESS score that is based on known drug-target activity profiles. Our results illustrate that this modular approach is promising for repositioning drugs for use in polygenic diseases such as PD, and is capable of addressing challenges of the hindered gene target in drug repositioning approaches to date.

A transcriptome based approach to predict candidate drug targets and drugs for Parkinson's disease using an in vitro 6-OHDA model

Druggable transcriptomic pathways revealed in Parkinson's patient-derived midbrain neurons

Druggable targets for Parkinson's disease: transcriptomics based Mendelian randomization study

Repositioning Drugs by Targeting Network Modules: a Parkinson's Disease Case Study.

Transcriptomic Profiling of Differentially Expressed Genes and Related Pathways in Different Brain Regions of Parkinson’s Disease

Transcriptome-based biomarker prediction for Parkinson's disease using genome-scale metabolic modeling

Identifying Genetic Targets in Clinical Subtypes of Parkinson’s Disease for Optimizing Pharmacological Treatment Strategies

Transcriptomics analysis of human iPSC-derived dopaminergic neurons reveals a novel model for sporadic Parkinson's disease

Identifying genetic targets in clinical subtypes of Parkinson's disease for optimizing pharmacological treatment strategies

Identification of Potential Parkinson's Disease Drugs Based on Multi-Source Data Fusion and Convolutional Neural Network

Insights into dietary phytochemicals targeting Parkinson's disease key genes and pathways: A network pharmacology approach

Prediction of Inhibitors Against Alpha-Synuclein Fibrils Formed in Parkinson’s Disease

Drug repurposing for Parkinson's disease by biological pathway based edge-weighted network proximity analysis

Transcriptomic Profiling of Differentially Expressed Genes and Related Pathways in Different Brain Regions in Parkinson's Disease.

Deep-learning-based target screening and similarity search for the predicted inhibitors of the pathways in Parkinson's disease

Transcriptome Sequencing in a 6-Hydroxydopamine Rat Model of Parkinson’s Disease

Uncovering the Pharmacology of Ginkgo Biloba Folium in the Cell-Type-specific Targets of Parkinson's Disease.

Drug Repurposing for Parkinson's Disease Using Random Walk With Restart Algorithm and the Parkinson's Disease Ontology Database

In Vivo Dopamine Neuron Imaging-Based Small Molecule Screen Identifies Novel Neuroprotective Compounds and Targets

<i>In Vivo</i> Dopamine Neuron Imaging-Based Small Molecule Screen Identifies Novel Neuroprotective Compounds and Targets

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics